Company / Return on Assets (ROA)
Monte Rosa Therapeutics, Inc. Return on Assets (ROA) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-16.6%
FY2024
5-year range
-72.7% / -16.6%
FY2020-FY2024
Trend
+62.8%
vs FY2023
Sector context
#94 of 213
Health Care
What the data says
At -16.6%, Monte Rosa Therapeutics, Inc.'s return on assets (roa) ranks #94 of 213 in the Health Care sector. Return on Assets (ROA) returned to growth in FY2024 after 2 years of decline, reaching -16.6%.
Based on SEC 10-K filings.
-16.6% in FY2024 with a 3-year CAGR of +3.6%.
Improved from -31.7% to -16.6% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +3.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#94 of 213 in Health CareTop 44% of 213This company -16.6% Sector average -24.1%
▼
+31.4% above sector average
Key checks
Key Insights
- In FY2024, return on assets (roa) increased 62.8% year-over-year.
- Currently 7.6pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -16.6% | +62.8% |
| FY2023 | -44.6% | -40.6% |
| FY2022 | -31.7% | -57.0% |
| FY2021 | -20.2% | +72.2% |
| FY2020 | -72.7% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026